<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746992</url>
  </required_header>
  <id_info>
    <org_study_id>CTOP</org_study_id>
    <nct_id>NCT01746992</nct_id>
  </id_info>
  <brief_title>CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma</brief_title>
  <official_title>An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      T cell lymphoma is a heterogenic malignancy with poor outcome. Five-year PFS and OS of the
      patients recieved classic CHOP regimen(cyclophosphamide,vincristin,doxorubicin and
      predisone)is less than 30%.High dose intensive chemotherapy doesn`t demonstrate better
      response. At present, there is no standardized treatment protocol for this kind of lymphoma.

      Between 1994 and 1998,the Scotland and Newcastle Lymphoma Group prospectively collected data
      on newly diagnosed patients with enteropathy associated T-cell lymphoma (EATL)in the Northern
      Region of England and Scotland,which is a rare and aggressive type of peripheral T-cell
      lymphoma.The novel regimen IVE/MTX (ifosfamide, vincristine, etoposide/methotrexate)-ASCT was
      piloted for patients eligible for intensive treatment,followed by auto-stem cell
      transplantation.Five-years PFS and OS were 52% and 60% respectively, significantly improved
      compared with the historical group treated with anthracycline-based chemotherapy. The
      encouraged results were extended to the peripherial T cell lymphoma-non specified(PTCL-nos).

      Past studies suggested pirarubicin was more active to the T cell lymphoma than doxorubicin in
      vitro based on its high concentration in tumor cells. Clinical data also presented equivalent
      even superior efficacy of pirarubicin with lower toxicity than doxorubicin. The aim of our
      study is to compare the response and survival rate of CTOP/ITE/MTX (cyclophosphamide,
      vincristin,pirarubicin and predisone/ ifosfamide, pirarubicin, etoposide/methotrexate) with
      those of CHOP regimen,looking forward to its superiority in efficacy and safety for the de
      novo young patients with T cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year PFS</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year os</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>ALK-negative Anaplastic Large Cell Lymphoma</condition>
  <condition>Peripherial T Cell Lymphoma,Not Otherwise Specified</condition>
  <condition>Angioimmunoblastic T Cell Lymphoma</condition>
  <condition>Enteropathy Associated T Cell Lymphoma</condition>
  <condition>Hepatosplenic T Cell Lymphoma</condition>
  <condition>Subcutaneous Panniculitis Like T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>pirarubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 cycles of CTOP(cyclophosphamide,vincristin,pirarubicin and prednisone),3 cycles of ITE(ifosfamide, pirarubicin, etoposide)and 2 cycles of methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>doxorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 cycles of CHOP regimen(cyclophosphamide,vincristin,doxorubicin and prednisone)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 750mg/m2</intervention_name>
    <description>day 1 in both arms</description>
    <arm_group_label>pirarubicin</arm_group_label>
    <arm_group_label>doxorubicin</arm_group_label>
    <other_name>CTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine 1.4mg/m2</intervention_name>
    <description>day 1</description>
    <arm_group_label>pirarubicin</arm_group_label>
    <arm_group_label>doxorubicin</arm_group_label>
    <other_name>VCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin 50mg/m2</intervention_name>
    <description>day 1</description>
    <arm_group_label>doxorubicin</arm_group_label>
    <other_name>ADM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone 60mg/m2</intervention_name>
    <description>day1-day5</description>
    <arm_group_label>pirarubicin</arm_group_label>
    <arm_group_label>doxorubicin</arm_group_label>
    <other_name>PRED</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide 2000mg/m2</intervention_name>
    <description>day 22-day 24</description>
    <arm_group_label>pirarubicin</arm_group_label>
    <other_name>IFO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pirarubicin 50mg/m2</intervention_name>
    <description>day 1</description>
    <arm_group_label>pirarubicin</arm_group_label>
    <other_name>THP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pirarubicin 25mg/m2</intervention_name>
    <description>day 22</description>
    <arm_group_label>pirarubicin</arm_group_label>
    <other_name>THP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide phosphate 100mg/m2</intervention_name>
    <description>day 22-day 24</description>
    <arm_group_label>pirarubicin</arm_group_label>
    <other_name>VP-16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate 1500mg/m2</intervention_name>
    <description>day 43</description>
    <arm_group_label>pirarubicin</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pathologic verified mature T cell lymphoma,including ALK-negative anaplastic large
             cell lymphoma,peripherial T cell lymphoma-non specific type,angioimmunoblastic T cell
             lymphoma,enteropathy associated T cell lymphoma and hepatosplenic T cell lymphoma

          -  SGOT/SGPT no more than 2 times of UNL

          -  serum creatinine no more than 1.5 times of UNL

          -  signed informed consent

        Exclusion Criteria:

          -  woman in pregnancy or lactation

          -  allergic to any intervention drug

          -  insuitable to the study due to severe complication

          -  enrolled to other study during the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ruijin hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Weili</investigator_full_name>
    <investigator_title>vice director of Department of Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Enteropathy-Associated T-Cell Lymphoma</mesh_term>
    <mesh_term>Panniculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

